Elizabeth B. Taylor
About Elizabeth B. Taylor
Elizabeth B. Taylor, age 49, is Chief Financial Officer of Sanara MedTech Inc. (SMTI) since January 2025, and briefly served as principal accounting officer beginning August 19, 2025 before that function was delegated to Ashley Mackey on August 29, 2025; Taylor continues as CFO and signs current SEC filings in that capacity . She holds a BA from Princeton University and an MBA from Harvard Business School; her career spans CFO and board service at Imbed Biosciences (2018–2025), founding a wealth advisory firm (2011–2023), COO roles at Citadel’s PioneerPath (2008–2010) and Tala Investments (2005–2008), and earlier private equity experience . SMTI’s performance context during her tenure-in begins with a multi‑year trajectory of revenue growth from FY2022 to FY2024 ($45.8M → $65.0M → $86.7M*) and improving EBITDA (−$9.7M → −$4.0M → −$1.4M*), with cumulative TSR at $112.35 for a $100 investment as of 12/31/2024; net losses were $9.7M in 2024, $4.3M in 2023, and $7.9M in 2022 . Values marked * are retrieved from S&P Global.
Past Roles
| Organization | Role | Years | Strategic Impact |
|---|---|---|---|
| Imbed Biosciences, Inc. | Chief Financial Officer | 2023–2025 | Led finance for privately held wound-care innovator; served on board 2018–2023, supporting commercialization strategy |
| Burnett Taylor Consulting, LLC | Founder; Financial Advisor | 2011–2023 | Advised high net worth clients on investments; built independent advisory platform |
| Citadel Investment Group (PioneerPath Capital) | Chief Operating Officer | 2008–2010 | Established and operated a start‑up division within a leading hedge fund; scaled ops and controls |
| Tala Investments, LP | Co‑Founder; Chief Operating Officer | 2005–2008 | Built a value hedge fund; led operations, risk, and execution |
| Private Equity (early career) | Investment Professional | Not disclosed | Foundation in transactions and portfolio value creation |
External Roles
| Organization | Role | Years | Strategic Impact |
|---|---|---|---|
| Imbed Biosciences, Inc. | Board Member | 2018–2023 | Governance and oversight for wound-care product development |
Fixed Compensation
- CFO-specific base salary, target bonus, and actual bonus are not disclosed in SMTI’s latest proxy and 8‑K filings for Taylor. Executive compensation is set by the Compensation Committee, which administers base salary, annual cash bonuses, and equity awards; executives participate in standard benefits and a 401(k) plan with dollar‑for‑dollar match on the first 4% of pre‑tax earnings .
Performance Compensation
- Not disclosed for Taylor (no published metrics, weightings, or payout formulas specific to the CFO).
Equity Ownership & Alignment
- Taylor’s beneficial ownership and vested/unvested equity holdings are not listed in the April 11, 2025 security ownership table covering directors and named executive officers .
- Hedging/pledging: SMTI’s insider trading policy prohibits hedging, short sales, options trading, holding shares in margin accounts, or pledging Company stock without advance approval of the CEO and CFO, signaling strong alignment controls .
Employment Terms
- Role transitions: The Company disclosed that Taylor would assume principal accounting officer duties effective August 19, 2025; on August 29, 2025, Ashley Mackey was designated principal accounting officer, and Taylor continued as CFO .
- Employment agreement, severance, change‑of‑control terms, non‑compete, and non‑solicit provisions are not disclosed for Taylor. General executive employment terms are described for other executives (CEO, CAO/CAAO, COO) but not for the CFO .
- Perquisites and clawbacks: SMTI maintains a Compensation Recovery Policy overseen by the Compensation Committee; perquisites are limited and not typical for executives .
SMTI Operating Performance
SMTI last 8 quarters:
| Metric | Q4 2023 | Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 |
|---|---|---|---|---|---|---|---|---|
| Revenues (USD) | 17,689,813 | 18,536,638 | 20,158,823 | 21,671,599 | 26,305,365 | 23,434,096 | 25,830,834 | 26,333,819 |
| EBITDA (USD) | −1,086,197* | −491,965* | −1,793,122* | 1,882,391* | −249,945* | −955,619* | 1,082,883* | 3,605,732* |
| Net Income (USD) | −237,194* | −1,764,184* | −3,504,014* | −2,857,768* | −1,538,581* | −3,527,177* | −2,014,362* | −30,411,153* |
| Diluted EPS – Continuing Ops (USD) | −0.0283* | −0.2095* | −0.4138* | −0.0210* | −0.1803* | −0.4116* | −0.2339* | 0.0900 |
| Cash from Operations (USD) | −848,532* | −1,594,370* | −1,411,930* | N/A* | 932,047* | −1,998,884* | 2,664,011* | N/A* |
SMTI last 3 fiscal years:
| Metric | FY 2022 | FY 2023 | FY 2024 |
|---|---|---|---|
| Revenues (USD) | 45,842,845 | 64,989,842 | 86,672,425 |
| EBITDA (USD) | −9,674,366* | −3,990,022* | −1,415,946* |
| Net Income (USD) | −7,937,497 | −4,303,197 | −9,664,547 |
| Diluted EPS – Continuing Ops (USD) | −1.0039* | −0.5198* | −1.1391* |
| Cash from Operations (USD) | −5,554,870* | −3,245,556* | −23,784* |
Cumulative TSR (value of initial $100 investment, year‑end):
| Period | FY 2022 | FY 2023 | FY 2024 |
|---|---|---|---|
| TSR ($) | 91.18 | 82.36 | 112.35 |
Values marked * are retrieved from S&P Global.
Compensation Committee Analysis
- Composition: Independent directors Roszell Mack III, Eric D. Major, and Sara N. Ortwein; chair: Sara N. Ortwein .
- Responsibilities: Reviews goals/objectives for executive pay, approves exec compensation and incentive equity plans, oversees Compensation Recovery Policy, and evaluates risk in incentive structures .
Risk Indicators & Red Flags
- Legal proceedings: Proxy reports no material legal proceedings involving directors or executive officers that would affect integrity or ability; no adverse party interests disclosed .
- Hedging/pledging controls: Company policy restricts hedging and pledging without advance approval, mitigating misalignment risk .
- Governance continuity: Taylor’s role adjustments in mid‑2025 were transparently disclosed, with continued CFO accountability evidenced by her signatures on 8‑K filings .
- Strategic events: In November 2025, SMTI announced a strategic realignment and discontinuation of Tissue Health Plus operations, reflecting portfolio focus; Taylor signed related filings .
Investment Implications
- Compensation transparency: Absence of CFO‑specific compensation and contract disclosures limits pay‑for‑performance assessment and retention risk quantification; monitor future proxies and any Item 5.02 filings for CFO employment terms and equity awards .
- Alignment: Strong corporate restrictions on hedging/pledging reduce misalignment risk; however, no visibility into Taylor’s personal ownership levels leaves equity alignment unverified .
- Execution context: Revenue growth and improving EBITDA into FY2024*, followed by 2025 restructuring, suggest a focus on surgical segment profitability; CFO continuity through these changes is supportive for controls and reporting, but 2025 losses and restructuring charges (reflected in quarterly net income*) warrant caution on near‑term incentive outcomes. Values marked * are retrieved from S&P Global.
- Signals to track: Upcoming DEF 14A for FY2025 should disclose CFO compensation structure, any performance metrics (e.g., revenue growth, EBITDA, TSR), and equity grants/vesting that could drive insider selling pressure; continue monitoring Form 4 filings for Taylor to assess vesting schedules and potential selling activity.